IMA Wealth Inc. Has $2.75 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IMA Wealth Inc. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,351 shares of the biopharmaceutical company’s stock after selling 255 shares during the period. IMA Wealth Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,748,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. JPMorgan Chase & Co. raised its holdings in Regeneron Pharmaceuticals by 11.9% during the 4th quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock worth $2,899,642,000 after purchasing an additional 489,084 shares during the last quarter. Putnam Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 43.1% in the 3rd quarter. Putnam Investments LLC now owns 1,342,754 shares of the biopharmaceutical company’s stock valued at $812,608,000 after acquiring an additional 404,567 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 13.6% in the 4th quarter. Geode Capital Management LLC now owns 1,977,302 shares of the biopharmaceutical company’s stock valued at $1,245,725,000 after acquiring an additional 237,090 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Regeneron Pharmaceuticals by 179.4% in the 4th quarter. Renaissance Technologies LLC now owns 282,962 shares of the biopharmaceutical company’s stock valued at $178,696,000 after acquiring an additional 181,700 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Regeneron Pharmaceuticals by 54.3% in the 4th quarter. Barclays PLC now owns 489,609 shares of the biopharmaceutical company’s stock valued at $309,201,000 after acquiring an additional 172,347 shares during the last quarter. Institutional investors and hedge funds own 83.83% of the company’s stock.

A number of brokerages have recently commented on REGN. Piper Sandler upped their price target on Regeneron Pharmaceuticals from $690.00 to $692.00 and gave the company an “overweight” rating in a research note on Friday, February 4th. Cowen upped their price target on Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. Cowen upped their price target on Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. StockNews.com raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 14th. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $718.74.

Shares of NASDAQ REGN traded down $7.84 during trading hours on Thursday, hitting $683.04. The company had a trading volume of 14,114 shares, compared to its average volume of 702,114. The stock has a market capitalization of $74.14 billion, a P/E ratio of 9.83, a price-to-earnings-growth ratio of 1.26 and a beta of 0.25. The company has a quick ratio of 4.09, a current ratio of 4.76 and a debt-to-equity ratio of 0.14. Regeneron Pharmaceuticals, Inc. has a 1-year low of $492.13 and a 1-year high of $747.42. The firm’s 50 day moving average is $681.76 and its 200-day moving average is $647.20.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share for the quarter, beating analysts’ consensus estimates of $9.37 by $2.12. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. The business had revenue of $2.97 billion for the quarter, compared to analysts’ expectations of $2.69 billion. During the same quarter in the prior year, the business earned $10.09 EPS. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 40.26 earnings per share for the current year.

In related news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $701.82, for a total value of $701,820.00. Following the transaction, the executive vice president now owns 22,014 shares in the company, valued at $15,449,865.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert E. Landry sold 325 shares of the firm’s stock in a transaction dated Friday, April 8th. The shares were sold at an average price of $737.79, for a total value of $239,781.75. Following the completion of the sale, the chief financial officer now directly owns 28,744 shares in the company, valued at $21,207,035.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,778 shares of company stock worth $26,133,901. 11.84% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.